Transition Metal Complexes as Therapeutics: A New Frontier in Combatting Neurodegenerative Disorders through Protein Aggregation Modulation
Authors:
- 2 September 2024
- journal article
- research article
- Published by Wiley in Advanced Healthcare Materials
- Vol. 13 (31) , e2401991
Abstract
Neurodegenerative disorders (NDDs) are a class of debilitating diseases that progressively impair the protein structure and result in neurological dysfunction in the nervous system. Among these disorders, Alzheimer's disease (AD), prion diseases such as Creutzfeldt‐Jakob disease (CJD), and Parkinson's disease (PD) are caused by protein misfolding and aggregation at the cellular level. In recent years, transition metal complexes have gained significant attention for their potential applications in diagnosing, imaging, and curing these NDDs. These complexes have intriguing possibilities as therapeutics due to their diverse ligand systems and chemical properties and can interact with biological systems with minimal detrimental effects. This review focuses on the recent progress in transition metal therapeutics as a new era of hope in the battle against AD, CJD, and PD by modulating protein aggregation in vitro and in vivo. It may shed revolutionary insights into unlocking new opportunities for researchers to develop metal‐based drugs to combat NDDs.Keywords
Funding Information
- National Research Foundation of Korea (NRF‐2022R1A3B1077319)
- Indian Institute of Technology Roorkee
- Human Resource Development Centre, Council of Scientific And Industrial Research
This publication has 218 references indexed in Scilit:
- α‐Synuclein as a Target for Metallo‐Anti‐Neurodegenerative AgentsAngewandte Chemie International Edition, 2022
- Coordination of Platinum to α‐Synuclein Inhibits Filamentous Aggregation in SolutionChemBioChem, 2019
- A Metallo Pro‐Drug to Target CuII in the Context of Alzheimer's DiseaseChemistry – A European Journal, 2018
- An Iridium(III) Complex as a Photoactivatable Tool for Oxidation of Amyloidogenic Peptides with Subsequent Modulation of Peptide AggregationChemistry – A European Journal, 2016
- Modulation of Amyloid‐β Aggregation by Histidine‐Coordinating Cobalt(III) Schiff Base ComplexesChemBioChem, 2014
- Development of a Platinum Complex as an anti‐Amyloid Agent for the Therapy of Alzheimer’s DiseaseAngewandte Chemie International Edition, 2013
- Identification of [PtCl2(phen)] Binding Modes in Amyloid‐β Peptide and the Mechanism of Aggregation InhibitionChemistry – A European Journal, 2011
- Pathogenic protein seeding in alzheimer disease and other neurodegenerative disordersAnnals of Neurology, 2011
- Interaction of the Human Prion Protein PrP106–126 with Metal Complexes: Potential Therapeutic Agents Against Prion DiseaseChemistry – A European Journal, 2010
- Cleavage Agents for Soluble Oligomers of Amyloid β PeptidesAngewandte Chemie International Edition, 2007